FR05C0022I2 - - Google Patents

Info

Publication number
FR05C0022I2
FR05C0022I2 FR05C0022C FR05C0022C FR05C0022I2 FR 05C0022 I2 FR05C0022 I2 FR 05C0022I2 FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 I2 FR05C0022 I2 FR 05C0022I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR05C0022C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0022(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of FR05C0022I1 publication Critical patent/FR05C0022I1/fr
Application granted granted Critical
Publication of FR05C0022I2 publication Critical patent/FR05C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
FR05C0022C 1995-03-30 2005-05-09 Active FR05C0022I2 (enFirst)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
FR05C0022I1 FR05C0022I1 (enFirst) 2005-06-10
FR05C0022I2 true FR05C0022I2 (enFirst) 2005-10-21

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0022C Active FR05C0022I2 (enFirst) 1995-03-30 2005-05-09

Country Status (35)

Country Link
US (1) US6417191B1 (enFirst)
EP (1) EP0817637B1 (enFirst)
JP (1) JP2954357B2 (enFirst)
KR (1) KR100542536B1 (enFirst)
CN (1) CN1103593C (enFirst)
AP (1) AP652A (enFirst)
AT (1) ATE220551T1 (enFirst)
AU (1) AU715213B2 (enFirst)
BR (3) BRPI9607851B8 (enFirst)
CA (1) CA2216634C (enFirst)
CZ (1) CZ295940B6 (enFirst)
DE (3) DE122005000029I2 (enFirst)
DK (1) DK0817637T3 (enFirst)
EA (1) EA000626B3 (enFirst)
EE (1) EE04047B1 (enFirst)
ES (1) ES2179193T3 (enFirst)
FR (1) FR05C0022I2 (enFirst)
GE (1) GEP20022647B (enFirst)
HU (1) HU224010B1 (enFirst)
IL (1) IL117727A (enFirst)
LU (1) LU91171I2 (enFirst)
MX (1) MX9707316A (enFirst)
MY (1) MY115461A (enFirst)
NL (1) NL300195I2 (enFirst)
NO (2) NO313787B1 (enFirst)
NZ (1) NZ306419A (enFirst)
OA (1) OA10616A (enFirst)
PL (1) PL187085B1 (enFirst)
PT (1) PT817637E (enFirst)
RO (1) RO117995B1 (enFirst)
SI (1) SI0817637T1 (enFirst)
SK (1) SK283825B6 (enFirst)
TR (1) TR199701074T1 (enFirst)
UA (1) UA60293C2 (enFirst)
WO (1) WO1996030025A1 (enFirst)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Hivの治療に使用するためのvx478、ジドブジン、ftcおよび/または3tcを含んでなる組合わせ
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
EP1146882A2 (en) * 1998-05-29 2001-10-24 The University Of Florida Combination of zidovudine (azt) with nucleoside analogs for treatment of feline immunodeficiency virus
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
CA2677623C (en) * 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
EP4578865A3 (en) 2014-08-12 2025-07-30 Monash University Lymph directing prodrugs
JP7118888B2 (ja) 2015-09-08 2022-08-16 モナッシュ ユニバーシティ リンパ指向性プロドラッグ
EP3675838A4 (en) 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
CA3166908A1 (en) 2020-02-05 2021-08-12 Daniel Kenneth BONNER Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DK0513917T4 (da) 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger
ATE184787T1 (de) * 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Hivの治療に使用するためのvx478、ジドブジン、ftcおよび/または3tcを含んでなる組合わせ
BR9709951A (pt) 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado uso de éster de tetraidro-3-furilanila do ácido 3s[3r*(1r,2s*)]-[3-[[4-amino-enil)sulfonil](2-metilpropil]-2-hiroxi-1-fenilmetil)propil]-carbânico, zidovudino,e (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenteno-1-metanol e pacote para paciente
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
BR9607851B1 (pt) 2009-01-13
HK1009401A1 (en) 1999-09-10
DE122005000029I1 (de) 2005-10-06
NL300195I2 (nl) 2005-11-01
CZ295940B6 (cs) 2005-12-14
AU5497296A (en) 1996-10-16
EA000626B1 (ru) 1999-12-29
EE04047B1 (et) 2003-06-16
SI0817637T1 (en) 2002-10-31
HUP9801571A2 (hu) 1999-01-28
HUP9801571A3 (en) 2001-04-28
NO313787B1 (no) 2002-12-02
ATE220551T1 (de) 2002-08-15
EA199700203A1 (ru) 1998-02-26
ES2179193T3 (es) 2003-01-16
CA2216634C (en) 2004-07-20
CA2216634A1 (en) 1996-10-03
LU91171I2 (fr) 2005-07-04
DE122005000029I2 (de) 2006-04-27
PL187085B1 (pl) 2004-05-31
FR05C0022I1 (enFirst) 2005-06-10
CZ309097A3 (cs) 1998-05-13
WO1996030025A1 (en) 1996-10-03
MY115461A (en) 2003-06-30
BRPI9612992B1 (pt) 2020-08-04
EA000626B3 (ru) 2016-04-29
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
CN1103593C (zh) 2003-03-26
HU224010B1 (hu) 2005-04-28
SK129597A3 (en) 1998-07-08
AP9701089A0 (en) 1997-10-31
NO974510L (no) 1997-09-29
US6417191B1 (en) 2002-07-09
CN1185110A (zh) 1998-06-17
IL117727A (en) 1999-11-30
OA10616A (en) 2001-03-15
KR100542536B1 (ko) 2006-03-23
JP2954357B2 (ja) 1999-09-27
EP0817637A1 (en) 1998-01-14
LU91171I9 (enFirst) 2018-12-28
EP0817637B1 (en) 2002-07-17
GEP20022647B (en) 2002-03-25
JPH10511682A (ja) 1998-11-10
SK283825B6 (sk) 2004-02-03
EE9700240A (et) 1998-04-15
DE69622386D1 (de) 2002-08-22
NO2005014I2 (no) 2008-02-11
BRPI9607851B8 (pt) 2019-11-05
DE69622386T2 (de) 2003-02-13
RO117995B1 (ro) 2002-12-30
PL322532A1 (en) 1998-02-02
NO2005014I1 (no) 2005-06-06
MX9707316A (es) 1997-11-29
UA60293C2 (uk) 2003-10-15
AU715213B2 (en) 2000-01-20
IL117727A0 (en) 1996-07-23
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
BR9607851A (pt) 1998-07-21
AP652A (en) 1998-06-19
KR19980703420A (ko) 1998-11-05
NO974510D0 (no) 1997-09-29
DK0817637T3 (da) 2002-11-11

Similar Documents

Publication Publication Date Title
BRPI9612138B1 (enFirst)
FR05C0022I2 (enFirst)
FR2729268B1 (enFirst)
FR2730000B1 (enFirst)
FR2729686B1 (enFirst)
IN188139B (enFirst)
IN187218B (enFirst)
IN185793B (enFirst)
IN184955B (enFirst)
IN183362B (enFirst)
CN3035869S (enFirst)
CN3034189S (enFirst)
EP0742395A3 (enFirst)
EP0730889A3 (enFirst)
CN3037560S (enFirst)
CN3037433S (enFirst)
CN3037189S (enFirst)
CN3036648S (enFirst)
CN3036647S (enFirst)
CN3036463S (enFirst)
CN3035871S (enFirst)
CN3035870S (enFirst)
EP0879501A4 (enFirst)
CN3035868S (enFirst)
CN3035323S (enFirst)